课题基金 / 基金详情

A Novel Mechanism for LEF1 Promoter Regulation in Colon Cancer

A Novel Mechanism for LEF1 Promoter Regulation in Colon Cancer
结肠癌中 LEF1 启动子调控的新机制
批准号:
8718884
负责人:
Andria Denmon
金额:
$5.15万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-15 至 2016-09-14

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):在美国,结肠癌是癌症相关死亡的第三大原因,非裔美国人的发病率和死亡率高于其他任何种族。今年,美国癌症协会估计将有102480名美国人被诊断患有结肠癌,其中50830人将死于这种疾病。迄今为止,结直肠癌是与过度活跃、异常的Wnt信号有关的最臭名昭著的癌症。大多数病例源于大肠腺瘤性息肉病基因的失活突变,该基因编码b-连环蛋白破坏复合体的关键成分。稳定的细胞质b-连环蛋白的增加导致这种调节因子流入细胞核,在那里它与淋巴细胞增强因子/T细胞因子(LEF/ tcf)一起激活Wnt靶基因的转录,如CMYC和LEF1。LEF1基因座包含两个启动子。启动子1 (P1)是Wnt靶点,产生全长淋巴细胞增强因子-1 (FL-LEF-1),这是一种与b-连环蛋白协同作用的异构体;启动子2 (P2)产生显性阴性LEF-1 (dnLEF-1),这是一种缺乏b-连环蛋白结合域的异构体,因此可以下调Wnt靶基因。重要的是,只有wnt靶向的FL-LEF-1亚型在结肠癌中表达。产生dnLEF-1的P2启动子被一种未知机制主动沉默,该机制涉及上游抑制因子和多功能蛋白阴阳1 (YY1)。由于重新引入dnLEF-1可以通过结合Wnt靶基因下调来对抗Wnt信号传导,因此阐明其转录抑制机制并确定该调节因子如何在癌症中重新表达具有重要意义。提出以下目的和方法:1)确定YY1是否通过rna依赖机制沉默P2。提出了RNA免疫沉淀法和体外生化方法。2)确定上游抑制因子的核苷酸背景和相关蛋白。用于抑制的瞬时转染试验将用于定义元件内的核心序列。DNA亲和色谱和质谱将鉴定与这些关键序列相互作用的蛋白质。3)验证上游P1的转录影响下游P2的转录活性的假设。P1转录将使用定制设计的tale抑制因子进行调节。确定P2抑制的机制将有助于更好地理解多启动子基因位点的表达,从而强调在癌症和其他疾病中具有广泛影响和新的治疗方法的潜力。
英文摘要
DESCRIPTION (provided by applicant): In the United States, colon cancer is the third leading cause of cancer-related deaths with African-Americans having a higher incidence and mortality rate than any other ethnicity. This year, the American Cancer Society estimates that 102,480 Americans will be diagnosed with colon cancer and of those cases, 50,830 individuals will succumb to the disease. To date, colorectal cancer is the most notorious cancer linked to overactive, aberrant Wnt signaling. Most cases derive from inactivating mutations in the adenomatous polyposis coli gene, which encodes a key component of the b-catenin Destruction Complex. The increase in stable, cytoplasmic, b- catenin results in an influx of this regulator int the nucleus where it works with Lymphoid Enhancer Factor/T Cell Factors (LEF/TCFs) to activate transcription of Wnt target genes, such as CMYC and LEF1. The LEF1 locus contains two promoters. Promoter 1 (P1), which is a Wnt target, produces full-length Lymphoid Enhancer Factor-1 (FL-LEF-1), an isoform that works with b-catenin: promoter 2 (P2) produces dominate negative LEF-1 (dnLEF-1), an isoform that lacks the b-catenin binding domain, and can therefore down-regulate Wnt target genes. Importantly, only the Wnt-targeted FL-LEF-1 isoform is expressed in colon cancer. The dnLEF-1 producing P2 promoter is actively silenced by an unknown mechanism involving an upstream repressor element and the multifunctional protein, Yin Yang 1 (YY1). Since re-introduction of dnLEF-1 can oppose Wnt signaling by binding to Wnt target genes for downregulation, it is important to elucidate the mechanism of its transcriptional repression and determine how this regulator can be re-expressed in cancer. The following aims and methods are proposed: 1) Determine whether YY1 uses an RNA-dependent mechanism to silence P2. RNA immunoprecipitation assays and in vitro biochemical approaches are proposed. 2) Define the nucleotide context and associated proteins of the upstream repressor element. A transient transfection assay for repression will be used to define the core sequences within the element. DNA affinity chromatography and mass spectrometry will identify proteins interacting with these key sequences 3) Test the hypothesis that transcription from upstream P1 affects transcriptional activity of downstream P2. P1 transcription will be modulated using a custom designed TALE-repressor. Defining the mechanism of P2 repression will lead to a better understanding of expression from multi-promoter gene loci, and thus highlight the potential for broad impact and new therapeutic approaches in cancer and other diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金